Schmid John P. 4

What Happened

• John P. Schmid, a director of ANAPTYSBIO, reported the conversion/settlement of 6,030 derivative units into 6,030 shares of common stock on June 15, 2026. The transaction is reported as an exercise/conversion of a derivative (code M) with an acquisition price of $0.00—i.e., the RSUs vested and were settled for shares at no cash consideration. There is also a corresponding entry extinguishing the derivative (6,030 units disposed as derivative), which reflects the conversion rather than a market sale.

Key Details

• Transaction date: 2026-06-15 (Filed: 2026-06-17 — timely reporting)
• Transaction type: RSU vesting/derivative conversion (Form 4 code M)
• Shares acquired: 6,030 common shares at $0.00 per share (no cash paid)
• Derivative extinguished: 6,030 RSU units (reported as disposed at $0.00)
• Shares owned after transaction: not specified in the filing
• Footnotes: F1 — each RSU converts into 1 share for no consideration; F2 — 100% of the RSUs vested on June 15, 2026, subject to continued service
• No open-market sale or purchase reported as part of this filing

Context

• This was not a cash purchase or an open-market sale—it's the routine vesting/settlement of previously granted restricted stock units. Such settlements reflect compensation becoming actual stock rather than a decision to buy or sell shares on the market.